Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population

Hyun-Woong Cho; Jin Hwa Hong; Kyung Jin Min; Yung-Taek Ouh; Seok Ju Seong; Jun Hye Moon; Seong Hwan Cho; Jae Kwan Lee

doi:10.4143/crt.2020.1165

Articles

Page Path: HOME > Cancer Res Treat > Volume 53(3); 2021 > Article

Original Article Gynecologic Cancer Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population: Hyun-Woong Cho¹, Jin Hwa Hong¹, Kyung Jin Min², Yung-Taek Ouh³, Seok Ju Seong⁴, Jun Hye Moon⁵, Seong Hwan Cho⁵, Jae Kwan Lee¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2021;53(3):829-836.
DOI: https://doi.org/10.4143/crt.2020.1165
Published online: December 24, 2020

¹Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

²Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

³Department of Obstetrics and Gynecology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea

⁴Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea

⁵Sejong Biomed Co., Ltd., Paju, Korea

Correspondence: Jae Kwan Lee, Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea,
Tel: 82-2-2626-3142, Fax: 82-2-838-1560, E-mail: jklee38@korea.ac.kr

• Received: November 9, 2020 • Accepted: December 23, 2020

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

6,430 Views
188 Download
10 Crossref

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Abstract

Purpose
The study aimed to evaluate the diagnostic accuracy of polymerase chain reaction–based high-risk human papillomavirus (HPV) assays on self-collected vaginal and urine samples for detection of precancerous cervical lesions in referral population.
Materials and Methods
Women referred for colposcopy following abnormal cytology, were included this study. A total of 314 matched urine, vaginal, and cervical samples were collected. All samples were tested for HPV DNA using the RealTime HR-S HPV and Anyplex II HPV 28 assays. Primary endpoints were sensitivity for cervical intraepithelial neoplasia (CIN) 2+/CIN3+ and specificity for <CIN2. Secondary endpoints were the relative accuracy of high-risk HPV (hrHPV) test results in vaginal and urine samples versus cervical samples.
Results
The sensitivity of Realtime HR-S and Anyplex HPV assay was 93.13% (95% confidence interval [CI], 87.36 to 96.81) and 90.08% (95% CI, 83.63 to 94.61) for CIN2+ (n=130); specificity for <CIN2 was 32.69% (95% CI, 25.03 to 38.97) and 33.33% (95% CI, 26.26 to 41.00), respectively. Relative sensitivity of Realtime HR-S and Anyplex HPV tests for the detection of CIN2+ in vaginal versus cervical samples were 0.91 (95% CI, 0.90 to 1.03) and 0.87 (95% CI, 0.75 to 1.02), respectively; urine versus cervical comparisons were 0.79 (95% CI, 0.70 to 0.92) and 0.74 (95% CI, 0.61 to 0.89).
Conclusion
The detection performance for hrHPV and CIN2+ on self-collected vaginal samples was comparable to that of clinician-collected cervical samples. On the other hand, HPV tests using urine were inferior to those using clinician-collected cervical samples in terms of detecting hrHPV and CIN2+.
Key words: Cervical intraepithelial neoplasia, Human papillomavirus DNA tests, Specimen handling, Urine

Introduction

Human papillomavirus (HPV) is well established as the main cause of cervical cancer [1]. HPV testing has very high sensitivity for detecting cervical precancerous lesions defined as high-grade squamous intraepithelial lesions (HSIL) [2,3].

However, a major obstacle to controlling cervical cancer is the lack of participation in screening programs. In developed countries, such as the United Kingdom and the United States, 20%–30% of women of screening age have not been screened within the past 5 years or have never been screened [4]. In countries without well-developed screening programs, the participation rate was low, and 50%–80% of women were not screened [5]. Recently, comparative modeling analysis suggests that both high HPV vaccination coverage and screening uptake will be necessary, particularly in countries with the highest burden, to achieve elimination of cervical cancer [6].

HPV test using non-invasive technique such as self-collected urine and vaginal sampling is feasible and may increase participation in screening programs [7,8]. An HPV test using self-collected vaginal samples showed a comparable clinical accuracy in detecting HSIL in a meta-analysis [9]. The IMPR-OVE study, a randomized controlled trial, suggested that HPV testing with a clinically-validated polymerase chain reaction (PCR)–based assay had similar accuracy between self-collected and clinician-collected samples in terms of detection of precursor lesions (HSIL) [10]. In addition, since the HPV test using urine seems to have good accuracy in detecting HPV infection, it could be an additional strategy for women who do not participate in regular screening programs [11].

The accuracy of self-collecting HPV has been shown by well-established evidence, but it still has some limitations. A meta-analysis showed that HPV testing had lower sensitivity when performed with self-collected samples than with clinician-collected samples [9]. Furthermore, only 8.8% of the women invited to the IMPROVE trial participated. This low participation rate might reflect reluctance to be included in a randomized trial [12]. In terms of the urine HPV test, there was substantial heterogeneity between the studies in terms of type of HPV test used, diverse methods, and disease outcomes. Moreover, the clinical sensitivity for detecting cervical cancer precursor lesions with urine-based HPV testing remains unknown [13].

The objective of this study was to determine the performance and diagnostic accuracy of PCR-based high-risk HPV assays on self-collected vaginal and urine samples for detection of precancerous cervical lesions in a large referral population and to compare the results with those using the same test from paired clinician-collected cervical samples collected at the same visit.

Materials and Methods

1. HPV URSELF study

A population-based study of women referred to colposcopy for abnormal cytology results was conducted at three medical centers in Korea between January 2018 and January 2020. Potential participants had to be between the ages of 20 and 60, not pregnant at the time of the study, and have had none of the following: previous treatment for cervical disease (including the loop electrosurgical excision procedure, cold knife conization, cryotherapy, and laser therapy), previous hysterectomy, prior chemotherapy, radiation treatment for cervical neoplasia or another concurrent cancer, and human immunodeficiency virus infection or acquired immune deficiency syndrome. Matched samples (clinician-collected cervical sample, self-collected vaginal, and urine samples) were collected from study participants within 1 week after their visit to the colposcopy center.

2. Sample collection and preparation

On the day each participant visited the colposcopy center, she was provided with a self-sampling kit consisting of a plastic brush (Flocked Swab, manufactured by Noble Biosciences, Inc., Hwaseong, Korea), PreservCyt Solution (ThinPrep, manufactured by Hologic, Marlborough, MA), a urine collection cup (BD Vacutainer, manufactured by BD Diagnostics, Franklin Lakes, NJ), and illustrated instructions. Participants were instructed to collect a vaginal sample by inserting the plastic brush one inch into the vagina, rotating the swab for 15 seconds, and then removing it. The brush was subsequently suspended in 5 mL of ThinPrep, PreservCyt Solution. Participants then underwent a pelvic exam during which the clinician-collected a cervical sample using a cervical brush (Cervical Brush, manufactured by Noble Biosciences, Inc.). This brush was also suspended in 5 mL of ThinPrep, PreservCyt Solution. On the morning of another day, participants were instructed to collect the initial flow of urine (first-void) samples (approximately 30 mL) with a urine collection cup. The clinician-collected cervical samples were used as a reference sample for HPV DNA detection. Cervical, vaginal, and urine samples were stored at 4°C and processed within 1 week [14].

3. HPV assay detail

DNA extraction was performed as previously described [15]. HPV genotyping was performed via two different methods, the RealTime HR-S HPV and Anyplex II HPV 28 assays, both of which were performed at the Korea University Guro Hospital. The procedures used for the two assays were performed as previously described [15].

4. Sample size

Based on previous studies on real-time PCR-based HPV testing using urine samples as in this study, we assumed the sensitivity for cervical intraepithelial neoplasia (CIN) 2+ was 90%, with a 95% confidence interval (CI) 81.2–98.8 [11,16]. The calculated minimum number of study participants with CIN2+ was 45. Based on previous literature, it was assumed that the prevalence of CIN2+ among women with abnormal cytology who were referred to colposcopic biopsy was 15% [17,18]. Therefore, the required sample size was 300 for this study.

5. Statistical analysis

The primary endpoint was the sensitivity and specificity of the assays to detect CIN2+ and CIN3+ in clinician-collected cervical samples and self-collected vaginal and urine samples. The relative accuracy of high-risk HPV (hrHPV) test results in vaginal and urine samples versus cervical samples was computed, and 95% CIs were calculated according to binomial distributions. McNemar’s test is a statistical test used to evaluate paired nominal data and can be used to compare the proportions of hrHPV positive results between self-collected vaginal/urine samples and clinician-collected cervical samples, while accounting for the correlation of multiple samples within subjects [19]. Anyplex II HPV 28 detects 19 hrHPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82), while RealTime HR-S detects 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Only the 14 HPV types detected by the latter assays were considered hrHPV types in this study. Confidence intervals were calculated, and the significance level was set at 0.05. The statistical analyses were performed using SPSS ver. 24.0 (IBM Corp., Armonk, NY) and MedCalc Software (MedCalc software, Mariakerke, Belgium).

Results

A flow diagram for this study is shown in Fig. 1. A total of 458 women agreed to provide clinician-collected cervical samples, self-collected vaginal samples, and first-void urine. Of these, 124 were excluded after enrollment because either a vaginal or urine sample was not collected, and 20 paired samples were further excluded due to invalid results or insufficient samples. Finally, matched samples (cervical, vaginal samples, and urine) were collected from 314 participants: 21 were diagnosed with CIN2, 104 were diagnosed with CIN3, and four were diagnosed with cervical cancer. The median age of the participants was 40±15.4 years.

1. The agreement in HPV detection using self-collected vaginal/urine samples compared to clinician-collected cervical samples and results of McNemar’s test

Table 1 shows the agreement between self-collected vaginal or urine samples and clinician-collected cervical samples. The agreement between Realtime HR-S and Anyplex II HPV tests for vaginal versus cervical samples was 85.03% (95% CI, 80.60 to 88.79) and 82.17% (95% CI, 77.47 to 86.24), respectively. There was no significant difference in hrHPV detection between cervical and vaginal samples (RealTime HR-S, p=0.079; Anyplex II HPV, p=0.350). The agreement between HPV tests in urine compared with cervical samples was lower than vaginal samples (RealTime HR-S: 78.03%; 95% CI, 73.03 to 82.48; and Anyplex II: 74.84%; 95% CI, 69.66 to 79.55). In addition, there was a significant difference in hrHPV detection between cervical and urine specimens (RealTime HR-S, p < 0.001; Anyplex II HPV, p < 0.001).

Table 2 presents the concordance between urine and vaginal HPV tests compared to cervical HPV tests according to age group. There was no significant difference in hrHPV detection between cervical and vaginal samples between all age groups as shown in Table 1. However, urine HPV tests showed a significant difference compared to cervical HPV tests in women aged in their 20s and 30s, but not in those aged in their 40s and 50s.

Table 3 shows the agreement for HPV tests between vaginal/urine samples and cervical samples according to cytologic results. When comparing the cervical and vaginal HPV, there was a statistical difference in the patients diagnosed with ASC-H (atypical squamous cells of a high-grade squamous intraepithelial lesion cannot be ruled out) and HSIL by cytology. Urine HPV tests showed a significant difference from cervical HPV tests in all cytology results.

2. Absolute sensitivity and specificity

As shown in Table 4 for the cervical samples, the sensitivity of Realtime HR-S and Anyplex II were 93.13% (95% CI, 87.36 to 96.81) and 90.08% (95% CI, 83.63 to 94.61), respectively. The specificity of the two HPV assays for detecting CIN2+ were 32.69% (Realtime HR-S: 95% CI, 25.03 to 38.97) and 33.33% (Anyplex II: 95% CI, 26.26 to 41.01) for detecting CIN2+.

For the vaginal samples, the sensitivity of Realtime HR-S and Anyplex II was 84.73% (95% CI, 77.41 to 90.42) and 78.63% (95% CI, 70.61 to 85.30) for CIN2+, respectively. The specificity of Realtime HR-S and Anyplex II was 26.79% (95% CI, 20.25 to 34.15) and 29.17% (95% CI, 22.42 to 36.66), respectively. The sensitivities of the urine HPV test were slightly lower than those of cervical or vaginal HPV tests (Realtime HR-S: 73.28%; 95% CI, 64.85 to 80.63; Anyplex II: 66.41%; 95% CI, 57.61 to 74.42). The specificity of Realtime HR-S and Anyplex II was 32.14% (95% CI, 25.16 to 39.77) and 46.43% (95% CI, 38.71 to 54.27), respectively.

3. Relative sensitivity and specificity

The relative sensitivities and specificities for detecting CIN2+ in all samples are presented in Table 5. The sensitivity of HPV tests from vaginal samples was lower, but not significantly different compared to that of cervical samples (Realtime HR-S: 0.91; 95% CI, 0.80 to 1.04; Anyplex II: 0.87; 95% CI, 0.75 to 1.02). However, the relative sensitivity of HPV tests on urine specimens was significantly lower than cervical HPV tests (Realtime HR-S: 0.79; 95% CI, 0.70 to 0.92; Anyplex II: 0.74; 95% CI, 0.61 to 0.89). There was no significant difference in specificity for detecting CIN2+ between vaginal/urine samples compared with cervical samples.

Discussion

In this study, the paired sensitivity differences for detecting CIN2+ between cervical versus vaginal sampling were not significant, but the sensitivity of hrHPV tests on urine was significantly lower than that seen in cervical samples. In terms of concordance between samples, the agreement between hrHPV detection in self-collected vaginal and clinician-collected cervical samples was comparable, whereas there was a significant difference between self-collected urine and clinician-collected cervical samples with respect to the use of HPV tests to detect hrHPV infection.

Out results are in line with other studies that investigated the accuracy of HPV testing on self-collected vaginal samples. Previous studies including clinical trial and meta-analysis showed that HPV testing on self-collected vaginal samples had similar accuracy to clinician-collected cervical samples [9,10,20]. A 2014 meta-analysis showed that although the pooled sensitivity of HPV testing on self-samples was lower than HPV testing on a clinician-taken sample (ratio, 0.88 [95% CI, 0.85 to 0.91] for CIN2 or worse and 0.89 [0.83 to 0.96] for CIN3 or worse), PCR-based HPV tests generally showed similar sensitivity for both self-samples and clinician-based samples [9]. An updated meta-analysis also showed that when used with hrHPV assays based on PCR, testing on self-collected samples was similarly accurate as on clinician samples (pooled ratio of sensitivity for CIN2+, 0.99; 95% CI, 0.97 to 1.02) [20]. In a randomized, non-inferiority trial, HPV testing performed with a clinically-validated PCR-based assay had similar accuracy for self-collected and clinician-collected samples in terms of detection of CIN2+ or CIN3+ lesions [10].

This study showed that the hrHPV positivity and sensitivity for CIN2+ in urine was significantly lower than in cervical samples. Although many recent studies including meta-analyses that reported that PCR-based HPV testing on urine samples seemed to have good accuracy for detection of HPV [11,21–23], there was substantial heterogeneity between the studies. A 2014 meta-analysis of 14 studies reported a pooled sensitivity of 77% and specificity of 88% for urine detection of hrHPV [11]. Senkomago et al. demonstrated that the sensitivity of HPV tests in urine for CIN2+ detection was high (89.9%; 95% CI, 62.7 to 99.6) [24]. Cuzick et al. [13] showed the sensitivity from urine was slightly, but not significantly, lower (CIN3+, 91.4% [95% CI, 83.0 to 96.5]; p=0.300; CIN2+, 88.3% [95% CI, 81.9 to 93.0]; p=0.060). On the other hand, in a PaVDaG study, which is a population-based study, the relative sensitivity of hrHPV positivity for the detection of CIN2+ in urine versus cervical comparisons was significantly low (0.53; 95% CI, 0.42 to 0.67) [19]. Asciutto et al. showed that detection of hrHPV in urine samples had a sensitivity of 76.3% (95% CI, 67.9 to 84.2) for HSIL, which is similar to our results [25]. Therefore, evidence regarding clinical performance including sensitivity for detecting precancerous lesions with HPV testing on urine samples has been lacking until now [13].

There may be several reasons why the urine HPV test is less sensitive compared with cervical HPV tests in this study. First, since two HPV assays (Realtime HR-S and Anyplex II) were performed from one self-collected sample in the study, the amount of that sample might not have been sufficient. Moreover, because self-collected vaginal or urine samples did not contain enough exfoliated cervical cells for detection, this insufficient amount may have degraded the clinical performance of the self-collected vaginal samples [26]. Second, an uncontrolled urine sampling technique such as sampling at home has the risk of detecting HPV infections not correlated to the cervix and interacts negatively with test performance. Third, because the study did not use a chelating agent to collect cell-free DNA, this may be associated with the low concordance seen in the urine samples [27]. Previous studies have detected a substantial amount of non-cell-associated DNA, and a chelating agent can be used to avoid degradation of cell-free DNA [15]. Finally, there might have been DNA degradation in sample storage, due to urine collection without a preservative.

Additionally, the patient’s age may have influenced the outcome. There was no significant difference in hrHPV detection between cervical and urine samples in women aged 40–50. In a PaVDaG study, there was a 38% (24% to 57%) higher HPV detection rate in vaginal self-samples from women over 50 years compared with those ≤ 29 years [19]. Further studies are needed on the clinical performance of the urine HPV test according to age.

This study has several limitations. First, because a referral population was enrolled in this study, there may be limitations in evaluating the clinical performance of HPV testing on urine and vaginal samples. Previous studies have shown that a referral population is usually provides an efficient and accurate measure of sensitivity in a screening context, but its higher HPV positivity rate may make it is less reliable for assessing specificity [13]. Further studies are needed to validate the clinical performance of the Realtime HR-S and Anyplex II HPV tests with urine and vaginal sampling, especially for specificity in a screening population. Second, DNA extracts from participant urine and vaginal samples were divided for two kinds of HPV assays. Therefore, the reliability of the HPV test may deteriorate due to an insufficient amount of DNA. However, samples with incomprehensible results or invalid internal controls were excluded from analysis in this study. In addition, loss of urine during self-sampling at home and non-use of chelating agents and preservatives may be negative factors to lower the sensitivity of the urine HPV test.

Regardless of the limitations, the current study is the first Korean study to evaluate the clinical performance of PCR-based HPV tests using paired urine, vaginal, and cervical samples for detection of precancerous cervical lesions in high-risk women.

In conclusion, test performance to detect hrHPV and CIN2+ on self-collected vaginal samples was comparable with that of clinician-collected cervical samples. On the other hand, HPV tests using urine were inferior to those using clinician-collected cervical samples in terms of detecting HPV and CIN2+. HPV testing from self-collected vaginal samples may be useful for women who do not obtain cervical screening. Further research is needed to increase the sensitivity of urine HPV tests and optimize sampling methods.

NOTES

Ethical Statement

We obtained medical ethical approval from the institutional ethics boards of Korea University Guro Hospital (2018GR0114), Korea University Ansan Hospital (2018AS0252) and CHA Gangnam Medical Center (GCI1648), and all women provided informed consent to participate in the study. The study was registered in the ClinicalTrial.gov (NCT03409471,https://clinicaltrials.gov/ct2/show/NCT03409471?cond=urine+hpv&draw=2&rank=3).

Author Contributions

Conceived and designed the analysis: Cho HW, Lee JK.

Collected the data: Cho HW, Hong JH, Min KJ, Ouh YT, Seong SJ, Lee JK, Moon JH, Cho SH.

Contributed data or analysis tools: Cho HW, Lee JK, Min KJ, Ouh YT, Moon JH, Cho SH, Hong JH.

Performed the analysis: Cho HW, Hong JH, Min KJ, Ouh YT, Seong SJ, Moon JH, Cho SH, Lee JK.

Drafting of the manuscript: Cho HW.

Wrote the paper: Cho HW, Hong JH, Min KJ, Ouh YT, Seong SJ, Lee JK.

Obtaining funding: Cho HW, Moon JH, Cho SH, Lee JK.

Critical revision of the manuscript: Min KJ, Ouh YT, Seong SJ, Hong JH.

Study supervision: Lee JK.

Conflicts of Interest

The authors from Sejong Medical Co. are employees of and/or shareholders of the company, which developed the RealTime HR-S HPV assay. The remaining authors declare no competing financial interests.

Acknowledgements

This research was supported by a grant by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI17C2229). We thank all members of the research team at Sejong Medical CO., for technical support.

Fig. 1

Study flow diagram. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Table 1

Overall agreement between clinician-collected cervical and self-collected vaginal/urine samples

Comparison of samples	Realtime HR-S HPV							Anyplex II HPV

	+/+	+/ −	−/+	−/ −	Agreement %	95% CI^a)	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
Cervical vs. vaginal	217	30	17	50	85.03	80.60–88.79	0.079	198	32	24	60	82.17	77.47–86.24	0.350

Cervical vs. urine	194	53	16	51	78.03	73.03–82.48	< 0.001	164	66	13	71	74.84	69.66–79.55	< 0.001

CI, confidence interval; HPV, human papillomavirus.

^a) Two-tailed McNemar’s test.

Table 2

Agreement between clinician-collected cervical and self-collected vaginal/urine samples according to age groups

Age group (yr)	No.	Comparison of samples	Realtime HR-S HPV							Anyplex II HPV

			+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
≥ 50	32	Cervical vs. vaginal	15	2	4	11	81.25	63.56–92.79	0.688	14	4	4	10	75.00	56.60–88.54	> 0.99

		Cervical vs. urine	15	2	3	12	84.38	67.21–94.73	> 0.99	14	4	2	12	81.25	63.56–92.79	0.688

40–49	65	Cervical vs. vaginal	45	10	5	5	76.92	64.81–86.47	0.302	46	9	5	5	78.46	66.51–87.70	0.424

		Cervical vs. urine	46	9	3	7	81.54	69.97–90.08	0.146	42	13	4	6	73.85	61.46–83.97	0.049

30–39	141	Cervical vs. vaginal	98	12	6	25	87.23	80.88–92.26	0.238	89	12	9	31	85.11	78.14–90.54	0.664

		Cervical vs. urine	85	25	8	23	76.60	68.73–83.31	0.005	73	28	6	34	75.89	67.97–82.69	< 0.001

20–29	76	Cervical vs. vaginal	59	6	2	9	89.47	80.31–95.35	0.289	49	7	6	14	82.90	72.53–90.57	> 0.99

		Cervical vs. urine	48	17	2	9	75.00	63.74–84.23	0.001	35	21	1	19	71.05	59.52–80.89	< 0.001

CI, confidence interval; HPV, human papillomavirus.

^a) Two-tailed McNemar’s test.

Table 3

Agreement between cervical and vaginal/urine samples according to cytology

Comparison samples	Cytology	No.	Realtime HR-S HPV							Anyplex II HPV

			+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
Cervical vs. vaginal	All	314	217	30	17	50	85.03	80.60–88.79	0.079	198	32	24	60	82.17	77.47–86.24	0.350

	ASCUS/LSIL	244	159	23	17	45	83.61	78.35–88.02	0.430	144	21	23	56	81.97	76.56–86.58	0.880

	ASC-H/HSIL	70	58	7	0	5	90.00	80.48–95.88	0.016	54	11	1	4	82.86	71.97–90.82	< 0.001

Cervical vs. urine	All	314	194	53	16	51	78.03	73.03–82.48	< 0.001	164	66	13	71	74.84	69.66–79.55	< 0.001

	ASCUS/LSIL	244	143	39	14	48	78.28	72.57–83.29	0.001	117	48	13	66	75.00	69.08–80.30	< 0.001

	ASC-H/HSIL	70	51	14	2	3	77.14	65.55–86.33	0.002	47	18	0	5	74.29	62.44–83.99	< 0.001

ASC-H, atypical squamous cells of a high-grade squamous intraepithelial lesion cannot be ruled out; ASCUS, atypical squamous cells of undetermined significance; CI, confidence interval; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.

^a) Two-tailed McNemar’s test.

Table 4

Clinical performance of HPV test to detect CIN2+ in clinician-collected cervical, self-collected vaginal and urine samples

	Realtime HR-S HPV		Anyplex II HPV

	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Cervical	93.13 (87.36–96.81)	32.69 (25.03–38.97)	90.08 (83.63–94.61)	33.33 (26.26–41.01)

Vaginal	84.73 (77.41–90.42)	26.79 (20.25–34.15)	78.63 (70.61–85.30)	29.17 (22.42–36.66)

Urine	73.28 (64.85–80.63)	32.14 (25.16–39.77)	66.41 (57.61–74.42)	46.43 (38.71–54.27)

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Table 5

Relative sensitivity/specificity of HPV test to detect CIN2+ in self-collected vaginal and urine samples compared with clinician-collected cervical samples

Comparison of samples	Realtime HR-S HPV		Anyplex II HPV

	Relative sensitivity (95% CI)	Relative specificity (95% CI)	Relative sensitivity (95% CI)	Relative specificity (95% CI)
Cervical vs. vaginal	0.91 (0.80–1.04)	0.82 (0.52–1.37)	0.87 (0.75–1.02)	0.88 (0.55–1.38)

Cervical vs. urine	0.79 (0.70–0.92)	0.98 (0.65–1.59)	0.74 (0.61–0.89)	1.39 (0.94–2.07)

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

REFERENCES

1. Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24:769–72. Article PubMed
2. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908–13. Article PubMed PMC
3. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50:1867–73. Article PubMed PMC
4. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006;119:2372–5. Article PubMed
5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23. Article PubMed
6. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–90. Article PubMed PMC
7. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101. Article PubMed
8. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32. Article PubMed
9. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15:172–83. Article PubMed
10. Polman NJ, Ebisch RM, Heideman DA, Melchers WJ, Bekkers RL, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20:229–38. Article PubMed
11. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014;349:g5264.Article PubMed PMC
12. Lynge E. Self-collected versus clinician-collected samples for HPV testing. Lancet Oncol. 2019;20:170–1. Article PubMed
13. Cuzick J, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, et al. Performance and diagnostic accuracy of a urine-based human papillomavirus assay in a referral population. Cancer Epidemiol Biomarkers Prev. 2017;26:1053–9. Article PubMed
14. Nilyanimit P, Chansaenroj J, Karalak A, Laowahutanont P, Junyangdikul P, Poovorawan Y. Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples using the HPV GenoArray Diagnostic assay. PeerJ. 2017;5:e3910.Article PubMed PMC
15. Cho HW, Ouh YT, Hong JH, Min KJ, So KA, Kim TJ, et al. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. J Virol Methods. 2019;269:77–82. Article PubMed
16. Bernal S, Palomares JC, Artura A, Parra M, Cabezas JL, Robles A, et al. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test. J Clin Virol. 2014;61:548–52. Article PubMed
17. Barcelos AC, Michelin MA, Adad SJ, Murta EF. Atypical squamous cells of undetermined significance: Bethesda classification and association with human papillomavirus. Infect Dis Obstet Gynecol. 2011;2011:904674.Article PubMed PMC
18. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol. 2009;113:115–9. Article PubMed
19. Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open. 2016;6:e010660.Article PubMed PMC
20. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Collaboration on Self-Sampling and HPV TestingDetecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.Article PubMed PMC
21. Enerly E, Olofsson C, Nygard M. Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol. 2013;5:67–79. Article PubMed PMC
22. Hagihara M, Yamagishi Y, Izumi K, Miyazaki N, Suzuki T, Kato H, et al. Comparison of initial stream urine samples and cervical samples for detection of human papillomavirus. J Infect Chemother. 2016;22:559–62. Article PubMed
23. Van Keer S, Tjalma WA, Pattyn J, Biesmans S, Pieters Z, Van Ostade X, et al. Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. Eur J Clin Microbiol Infect Dis. 2018;37:859–69. Article PubMed PMC
24. Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol. 2016;74:26–31. Article PubMed
25. Asciutto KC, Henningsson AJ, Borgfeldt H, Darlin L, Borgfeldt C. Vaginal and urine self-sampling compared to cervical sampling for HPV-testing with the Cobas 4800 HPV test. Anticancer Res. 2017;37:4183–7. PubMed
26. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine: a review of the literature. Eur J Clin Microbiol Infect Dis. 2012;31:627–40. Article PubMed
27. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis. 2014;33:2005–14. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Variables that impact HPV test accuracy during vaginal self collection workflow for cervical cancer screening
Laurence Vaughan, Devin Gary, Millie Shah, Lyndsay Lewellen, Laura Galbraith, Valentin Parvu
Gynecologic Oncology Reports.2024; 54: 101421. CrossRef
Clinical performance of a newly developed domestic urine‐based HPV test for cervical cancer screening in China
Hui‐Fang Xu, Xue‐Lian Zhao, Shuang Zhao, Shang‐Ying Hu, Xun Zhang, Fang‐Hui Zhao, You‐Lin Qiao
Journal of Medical Virology.2023;[Epub] CrossRef
Can HPV Test on Random Urine Replace Self-HPV Test on Vaginal Self-Samples or Clinician-Collected Cervical Samples?
Yu-Hsiang Shih, Lou Sun, Shih-Tien Hsu, Ming-Jer Chen, Chien-Hsing Lu
International Journal of Women's Health.2023; Volume 15: 1421. CrossRef
Preliminary Results of Feasibility and Acceptability of Self-Collection for Cervical Screening in Italian Women
Illari Sechi, Narcisa Muresu, Mariangela V. Puci, Laura Saderi, Arcadia Del Rio, Andrea Cossu, Maria R. Muroni, Santina Castriciano, Marianna Martinelli, Clementina E. Cocuzza, Giovanni Sotgiu, Andrea Piana
Pathogens.2023; 12(9): 1169. CrossRef
Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self‐collected samples
Christophe Pasquier, Stéphanie Raymond, Delphine Duchanois, Karine Sauné, Kevin Oliveira‐Mendes, Christophe Vayssiere, Jacques Izopet
Journal of Medical Virology.2023;[Epub] CrossRef
Comparison of Different Self-Sampling Devices for Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs): A Pilot Study
Illari Sechi, Clementina Cocuzza, Marianna Martinelli, Narcisa Muresu, Santina Castriciano, Giovanni Sotgiu, Andrea Piana
Healthcare.2022; 10(3): 459. CrossRef
The Potential of Urine for Human papillomavirus-related Cervical Cancer Prevention
Maryame Lamsisi, Guorong Li, Celine Chauleur, Moulay Mustapha Ennaji, Thomas Bourlet
Future Virology.2022; 17(7): 495. CrossRef
Evaluation of BD Onclarity™ HPV Assay on Self-Collected Vaginal and First-Void Urine Samples as Compared to Clinician-Collected Cervical Samples: A Pilot Study
Marianna Martinelli, Chiara Giubbi, Illari Sechi, Fabio Bottari, Anna Daniela Iacobone, Rosario Musumeci, Federica Perdoni, Narcisa Muresu, Andrea Piana, Robert Fruscio, Fabio Landoni, Clementina Elvezia Cocuzza
Diagnostics.2022; 12(12): 3075. CrossRef
Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature
Alexandros Daponte, George Michail, Athina-Ioanna Daponte, Nikoletta Daponte, George Valasoulis
Cancers.2021; 13(7): 1640. CrossRef
Diagnostic Test Accuracy of First-Void Urine Human Papillomaviruses for Presence Cervical HPV in Women: Systematic Review and Meta-Analysis
Peter Bober, Peter Firment, Ján Sabo
International Journal of Environmental Research and Public Health.2021; 18(24): 13314. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population

Cancer Res Treat. 2021;53(3):829-836. Published online December 24, 2020

DOI: https://doi.org/10.4143/crt.2020.1165

XML Download

Figure

Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population

Fig. 1 Study flow diagram. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Fig. 1

Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population

Table 1

Overall agreement between clinician-collected cervical and self-collected vaginal/urine samples

Comparison of samples	Realtime HR-S HPV							Anyplex II HPV

	+/+	+/ −	−/+	−/ −	Agreement %	95% CI^a)	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
Cervical vs. vaginal	217	30	17	50	85.03	80.60–88.79	0.079	198	32	24	60	82.17	77.47–86.24	0.350

Cervical vs. urine	194	53	16	51	78.03	73.03–82.48	< 0.001	164	66	13	71	74.84	69.66–79.55	< 0.001

CI, confidence interval; HPV, human papillomavirus.

^a)Two-tailed McNemar’s test.

Table 2

Agreement between clinician-collected cervical and self-collected vaginal/urine samples according to age groups

Age group (yr)	No.	Comparison of samples	Realtime HR-S HPV							Anyplex II HPV

			+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
≥ 50	32	Cervical vs. vaginal	15	2	4	11	81.25	63.56–92.79	0.688	14	4	4	10	75.00	56.60–88.54	> 0.99

		Cervical vs. urine	15	2	3	12	84.38	67.21–94.73	> 0.99	14	4	2	12	81.25	63.56–92.79	0.688

40–49	65	Cervical vs. vaginal	45	10	5	5	76.92	64.81–86.47	0.302	46	9	5	5	78.46	66.51–87.70	0.424

		Cervical vs. urine	46	9	3	7	81.54	69.97–90.08	0.146	42	13	4	6	73.85	61.46–83.97	0.049

30–39	141	Cervical vs. vaginal	98	12	6	25	87.23	80.88–92.26	0.238	89	12	9	31	85.11	78.14–90.54	0.664

		Cervical vs. urine	85	25	8	23	76.60	68.73–83.31	0.005	73	28	6	34	75.89	67.97–82.69	< 0.001

20–29	76	Cervical vs. vaginal	59	6	2	9	89.47	80.31–95.35	0.289	49	7	6	14	82.90	72.53–90.57	> 0.99

		Cervical vs. urine	48	17	2	9	75.00	63.74–84.23	0.001	35	21	1	19	71.05	59.52–80.89	< 0.001

CI, confidence interval; HPV, human papillomavirus.

^a)Two-tailed McNemar’s test.

Table 3

Agreement between cervical and vaginal/urine samples according to cytology

Comparison samples	Cytology	No.	Realtime HR-S HPV							Anyplex II HPV

			+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)	+/+	+/ −	−/+	−/ −	Agreement %	95% CI	McNemar p-value^a)
Cervical vs. vaginal	All	314	217	30	17	50	85.03	80.60–88.79	0.079	198	32	24	60	82.17	77.47–86.24	0.350

	ASCUS/LSIL	244	159	23	17	45	83.61	78.35–88.02	0.430	144	21	23	56	81.97	76.56–86.58	0.880

	ASC-H/HSIL	70	58	7	0	5	90.00	80.48–95.88	0.016	54	11	1	4	82.86	71.97–90.82	< 0.001

Cervical vs. urine	All	314	194	53	16	51	78.03	73.03–82.48	< 0.001	164	66	13	71	74.84	69.66–79.55	< 0.001

	ASCUS/LSIL	244	143	39	14	48	78.28	72.57–83.29	0.001	117	48	13	66	75.00	69.08–80.30	< 0.001

	ASC-H/HSIL	70	51	14	2	3	77.14	65.55–86.33	0.002	47	18	0	5	74.29	62.44–83.99	< 0.001

^a)Two-tailed McNemar’s test.

Table 4

Clinical performance of HPV test to detect CIN2+ in clinician-collected cervical, self-collected vaginal and urine samples

	Realtime HR-S HPV		Anyplex II HPV

	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Cervical	93.13 (87.36–96.81)	32.69 (25.03–38.97)	90.08 (83.63–94.61)	33.33 (26.26–41.01)

Vaginal	84.73 (77.41–90.42)	26.79 (20.25–34.15)	78.63 (70.61–85.30)	29.17 (22.42–36.66)

Urine	73.28 (64.85–80.63)	32.14 (25.16–39.77)	66.41 (57.61–74.42)	46.43 (38.71–54.27)

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Table 5

Relative sensitivity/specificity of HPV test to detect CIN2+ in self-collected vaginal and urine samples compared with clinician-collected cervical samples

Comparison of samples	Realtime HR-S HPV		Anyplex II HPV

	Relative sensitivity (95% CI)	Relative specificity (95% CI)	Relative sensitivity (95% CI)	Relative specificity (95% CI)
Cervical vs. vaginal	0.91 (0.80–1.04)	0.82 (0.52–1.37)	0.87 (0.75–1.02)	0.88 (0.55–1.38)

Cervical vs. urine	0.79 (0.70–0.92)	0.98 (0.65–1.59)	0.74 (0.61–0.89)	1.39 (0.94–2.07)

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Table 1 Overall agreement between clinician-collected cervical and self-collected vaginal/urine samples

CI, confidence interval; HPV, human papillomavirus.

Two-tailed McNemar’s test.

Table 2 Agreement between clinician-collected cervical and self-collected vaginal/urine samples according to age groups

CI, confidence interval; HPV, human papillomavirus.

Two-tailed McNemar’s test.

Table 3 Agreement between cervical and vaginal/urine samples according to cytology

Two-tailed McNemar’s test.

Table 4 Clinical performance of HPV test to detect CIN2+ in clinician-collected cervical, self-collected vaginal and urine samples

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.

Table 5 Relative sensitivity/specificity of HPV test to detect CIN2+ in self-collected vaginal and urine samples compared with clinician-collected cervical samples

CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.